Rapt Therapeutics Inc Expected To Post A Loss Of 56 Cents A Share: Earnings Preview

Rapt Therapeutics

08/11/2024 15:33

* RAPT Therapeutics Inc  RAPT.OQ   RAPT.O  is expected
to show no
change in quarterly revenue when it reports  results on November
11 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for RAPT Therapeutics Inc is
for a
loss of 56 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for RAPT
Therapeutics
Inc is 7.50​, above​ its last closing price of $3.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.72       -0.72      -0.71     Beat    1.4
 Mar. 31 2024  -0.80       -0.81      -0.79     Beat    2.3
 Dec. 31 2023  -0.86       -0.86      -0.80     Beat    6.8​
 Sep. 30 2023  -0.75       -0.75      -0.82     Missed  -8.9
 ​​Jun.        -0.79       -0.78      -0.66     Beat    15.6
 30 2023                                                
 Mar. 31 2023  -0.67       -0.68      -0.76     Missed  -11.8​
 Dec. 31 2022  -0.62       -0.65      -0.64     Beat    2.1
 Sep. 30 2022  -0.65       -0.67      -0.63     Beat    6
 This summary was machine generated November 8 at 15:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)